94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data

ConclusionCombination treatment with sitravatinib and tislelizumab was manageable and showed promising antitumor activity in patients with ovarian cancer.Clinical trial identificationNCT03666143.Editorial acknowledgementWriting assistance was provided by Ira Mills, PhD, of Ashfield Healthcare Communications.Legal entity responsible for the studyBeiGene.FundingBeiGene.DisclosureB. Gao: Advisory / Consultancy: Merck Sharp& Dohme. J. Goh: Advisory / Consultancy: Bristol-Myers Squibb, AstraZeneca, and Ipsen; Honoraria (self), Payment for speaking engagements: Merck Sharp& Dohme. B. Markman: Advisory / Consultancy: Novartis. M. Voskoboynik: Honoraria (self): AstraZeneca and MSD Oncology; Travel / Accommodation / Expenses: Bristol-Myers Squibb. H.K. Gan: Advisory / Consultancy: AbbVie, Bristol-Myers Squibb, and Merck Sharp& Dohme; Speaker Bureau / Expert testimony: Eisai and Merck Serono; Research grant / Funding (self): AbbVie. J. Coward: Advisory / Consultancy: Takeda and Merck Sharp& Dohme; Research grant / Funding (self): AstraZeneca. C. Chen: Shareholder / Stockholder / Stock options, Full / Part-time employment: BeiGene. X. Xiang: Shareholder / Stockholder / Stock options, Full / Part-time employment: BeiGene. J. Qiu: Shareholder / Stockholder / Stock options, Full / Part-time employment: BeiGene. Y. Xu: Shareholder / Stockholder / Stock options, Full / Part-time employment: BeiGene. L. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employme...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research